Overview
GPCR market data
Price History
GPCR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.80 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.68 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $15.80 – $94.90 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $3.5K · P/B 2.71.
Company news
Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity ModelBenzinga · Jun 22, 2026, 11:20 AM
Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga · Jun 11, 2026, 11:49 AM
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70Benzinga · Jun 11, 2026, 10:09 AM
Structure Therapeutics Publishes Phase 2b Aleniglipron Results In Nature Medicine, Reporting Up To 16.2% Weight Loss; Phase 3 Obesity Program On Track For Q3 2026Benzinga · Jun 5, 2026, 8:10 PM
8-K filing — Structure Therapeutics Inc. (GPCR)SEC EDGAR · May 7, 2026, 8:42 PM